Sutro Biopharma Misses by $0.26 as Revenue Falls 35% Short

Sutro Biopharma reported a quarterly loss of $1.90 per share on Thursday, missing the analyst consensus of ($1.64) by $0.26, according to FiscalAI. The miss was not confined to the bottom line. Revenue of $9.10 million fell short of the $14.11 million analysts expected — a shortfall of roughly 35 percent.

The numbers deserve a closer look before anyone draws conclusions. A $5.01 million revenue gap on a base of $14.11 million is substantial for a clinical-stage biotechnology company that funds itself through markets rather than product sales. Sutro reported no explanation in the release for why revenue landed where it did. What the release did not say matters as much as what it did: there is no guidance revision, no cash-runway figure, no restated timeline for the pipeline.

What did the market do with the numbers?

NASDAQ-listed STRO fell $0.67 on Thursday to close at $9.59. Trading volume reached 657,271 shares — more than double the average of 273,651 — which suggests the market treated the miss as information worth repricing quickly.

The trading data frames how far the stock has traveled:

• 12-month high: $43.85
• 12-month low: $7.15
• 50-day moving average: $13.61
• 200-day moving average: $22.60
• Market capitalization: $159.00 million

A stock trading at $9.59 against a 200-day average of $22.60 has lost more than half its longer-term reference price. The beta of 1.56 signals that the decline compounds in weak markets. A price-to-earnings ratio of -0.80 simply confirms the company is losing money; it says nothing about when that changes.

Where do the analysts stand?

The ratings record splits sharply, and the split is the story. Five firms acted recently:

• HC Wainwright reissued a "buy" rating on Friday, October 16.
• Wedbush restated an "outperform" rating and set a $60.00 price target on Thursday, October 15.
• Mizuho raised the stock to "strong-buy" on Wednesday, September 16.
• Stifel Nicolaus set a $48.00 target and a "buy" rating on Friday, August 7.
• Wall Street Zen cut the stock from "sell" to "strong sell" on Sunday.

The aggregate picture: two strong-buy ratings, ten buy ratings and one sell, per the tally cited in the report. MarketBeat records a consensus rating of "buy" with an average price target of $49.50.

Here the skeptic's arithmetic intrudes. A $49.50 average target against a $9.59 share price implies upside of roughly 416 percent. That gap reflects targets set months ago, before the stock's slide, not fresh conviction. Wall Street Zen's Sunday downgrade to "strong sell" is the only rating that postdates the earnings release, and it points the opposite way. The consensus number, in plain words, is stale.

What is actually in the pipeline?

Sutro Biopharma develops targeted cancer treatments, with research centered on antibody-drug conjugates (ADCs) — antibodies that deliver cancer-fighting drugs to selected cells. The company built its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology designed to support the design and production of biologic medicines.

Its clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1. The release offered no update on trial progress or regulatory milestones for either program. For a company with $159.00 million in market value and a widening loss, the pipeline is the only asset that can close the gap between $9.59 and $49.50 — and on that, Thursday's release stayed silent.

The market cut the price; the analysts, so far, have not.